At Granules, we focus on efficiently creating high-quality APIs in key therapeutic categories with dedicated installed capacity of 26,360 TPA in the Core business, 283 KL in the Emerging business and 152KL in the current CRAMS business.

We are one of the global leaders in Ibuprofen, Paracetamol, Metformin, Guaifenesin and Methocarbamol. Our focused API portfolio has made it possible for us to emerge as one of the most efficient and cost-effective manufacturers, globally. We serve the needs of our customers through four API facilities and one intermediate facility in Hyderabad and Vizag.

Through the acquisition of Auctus Pharma in 2014, 12 APIs have been added to our portfolio across several therapeutic categories.

In addition to efficiently streamlining the manufacturing processes for the existing list of products, our R&D team has developed and commercialized several products. Such product categories include anti- retrovirals, anti- hypertensives, anti-histamines, anti- infectives, analgesics, anti-coagulants, anti-fibriotics and platelet inhibitors. 

Research and development of APIs is based on advanced technology, intellectual property, expertise and knowledge of regulations. Product development is geared towards quality, safety and efficacy of drugs and cost efficiencies for our customers.